Cogent Biosciences Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Cogent Biosciences, Inc. (COGT) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Operating Activities
Net Income-255.86-192.41-140.24-72.27-74.81-31.83-34.53
Depreciation & Amortization4.353.595.881.990.721.241.32
Stock Based Compensation39.7430.6218.3711.696.020.000.00
Change in Working Capital11.6011.440.750.18-5.32-13.98-2.15
Change in Accounts Receivable0.000.000.000.002.000.000.00
Change in Accounts Payable1.364.812.362.75-2.450.000.00
Change in Other Working Capital10.24-1.70-1.61-2.58-3.550.000.00
Other Operating Activities-7.62-1.70-1.36-0.340.223.130.02
Net Cash from Operating Activities-207.79-153.62-118.64-58.76-35.85-41.51-32.49
Investing Activities
Capital Expenditures-0.57-2.80-6.86-1.720.320.03-0.55
Acquisitions0.000.000.000.008.100.000.00
Purchases of Investments-255.60-348.80-117.860.000.000.000.00
Sales/Maturities of Investments294.45253.7860.000.000.0022.99-9.98
Other Investing Activities0.000.000.000.008.100.000.00
Net Cash from Investing Activities38.28-97.82-124.72-1.728.4223.16-10.53
Financing Activities
Common Stock Issued213.34161.82174.3639.26140.560.1171.79
Other Financing Activities1.12-10.70-10.80-1.29-12.760.00-2.06
Net Cash from Financing Activities214.45163.54163.5637.98232.200.1170.35
Summary
Net Change in Cash44.94-87.91-79.80-22.51204.77-18.2527.33
Cash at Beginning of Period53.23141.14220.94243.4538.6856.9329.60
Cash at End of Period98.1753.23141.14220.94243.4538.6856.93
Free Cash Flow-208.36-156.42-125.50-60.48-35.85-41.34-33.04